Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Gainers
Why Adairs, Ausdrill, Domino's, & Mesoblast shares charged higher today
Share Gainers
Why the Mesoblast share price zoomed 7% higher today
Share Gainers
ALL ORDINARIES finishes lower Thursday: 8 shares you missed
Share Fallers
Is the Mesoblast share price a buy after today's announcement?
Share Fallers
Why BlueScope Steel, Mesoblast, Wesfarmers, & WiseTech Global shares dropped lower today
Share Gainers
Why the Mesoblast share price stormed 6% higher today
Share Fallers
Insider share buying can't stop the Starpharma share price sliding again today
Share Fallers
Why the Biotron Limited share price cratered today
Share Market News
ALL ORDINARIES finishes lower Friday: 8 shares you missed
Share Market News
Are Mesoblast shares ready to shoot higher?
Share Market News
ALL ORDINARIES finishes higher Monday: 8 shares you missed
Share Fallers
Why the Mesoblast Limited (ASX:MSB) share price is crashing lower today
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
